Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to 'smartly' combine 'targeted drugs and cell therapies' in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? / F. Patriarca, L. Giaccone, F. Onida, L. Castagna, B. Sarina, V. Montefusco, A. Mussetti, N. Mordini, E. Maino, R. Greco, J. Peccatori, M. Festuccia, F. Zaja, S. Volpetti, A. Risitano, R. Bassan, P. Corradini, F. Ciceri, R. Fanin, M. Baccarani, A. Rambaldi, F. Bonifazi, B. Bruno. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 17:7(2017 Jul 03), pp. 821-836. [10.1080/14712598.2017.1324567]

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

F. Onida;L. Castagna;A. Mussetti;R. Greco;P. Corradini;A. Rambaldi;
2017

Abstract

Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to 'smartly' combine 'targeted drugs and cell therapies' in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.
Allogeneic stem cell transplantation; graft-versus-tumor; monoclonal antibodies; new drugs; targeted therapy
Settore MED/15 - Malattie del Sangue
3-lug-2017
22-mag-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
2017%patriarca%EOBT.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 9.71 MB
Formato Adobe PDF
9.71 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/500024
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact